NASDAQ:NEO

NeoGenomics Stock Forecast, Price & News

$43.57
+0.47 (+1.09 %)
(As of 06/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$43.13
$43.79
50-Day Range
$36.62
$51.69
52-Week Range
$26.26
$61.57
Volume651,657 shs
Average Volume911,058 shs
Market Capitalization$5.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.69
30 days | 90 days | 365 days | Advanced Chart
Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.


NeoGenomics logo

About NeoGenomics

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.55 out of 5 stars

Medical Sector

502nd out of 2,100 stocks

Testing Laboratories Industry

1st out of 3 stocks

Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

Is NeoGenomics a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics
or view top-rated stocks.

What stocks does MarketBeat like better than NeoGenomics?

Wall Street analysts have given NeoGenomics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NeoGenomics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Tuesday, July 27th 2021.
View our earnings forecast for NeoGenomics
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) posted its quarterly earnings data on Wednesday, May, 5th. The medical research company reported ($0.04) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.01 by $0.05. The medical research company had revenue of $115.30 million for the quarter, compared to analyst estimates of $112.17 million. NeoGenomics had a negative net margin of 2.42% and a positive trailing twelve-month return on equity of 0.83%. The company's revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company posted ($0.07) earnings per share.
View NeoGenomics' earnings history
.

How has NeoGenomics' stock price been impacted by Coronavirus?

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NEO stock has increased by 75.8% and is now trading at $43.57.
View which stocks have been most impacted by COVID-19
.

How often does NeoGenomics pay dividends? What is the dividend yield for NeoGenomics?

NeoGenomics declared a dividend on Tuesday, December 15th. Shareholders of record on Friday, December 18th will be given a dividend of $0.40 per share on Wednesday, December 30th. This represents a dividend yield of 3.13%. The ex-dividend date is Thursday, December 17th.
View NeoGenomics' dividend history
.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of -0.270--0.230 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.200. The company issued revenue guidance of $490 million-$510 million, compared to the consensus revenue estimate of $498.21 million.

What price target have analysts set for NEO?

11 equities research analysts have issued 1-year target prices for NeoGenomics' stock. Their forecasts range from $14.50 to $65.00. On average, they anticipate NeoGenomics' stock price to reach $51.32 in the next year. This suggests a possible upside of 17.8% from the stock's current price.
View analysts' price targets for NeoGenomics
or view top-rated stocks among Wall Street analysts.

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:
  • Ms. Kathryn B. McKenzie, Chief Financial Officer (Age 37, Pay $534.62k)
  • Mr. Douglas M. Brown, Chief Strategy & Corp. Devel. Officer (Age 50, Pay $677.65k)
  • Mr. Mark W. Mallon, CEO & Director (Age 58)
  • Ms. Cynthia J. Dieter, Chief Accounting Officer & Controller (Age 46)
  • Charlie Eidson, Mang. of Investor Relations and Strategy & Corp. Devel.
  • Ms. Stephanie K. Bywater, Chief Compliance Officer (Age 50)
  • Mr. Marcus B. Silva J.D., M.B.A., Chief Marketing Officer (Age 45)
  • Mr. George A. Cardoza, Pres of Pharma Services Division (Age 59)
  • Ms. Jennifer M. Balliet, Chief Culture Officer (Age 44)
  • Mr. William Bishop Bonello, Pres of Informatics Division (Age 56)

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of NeoGenomics' key competitors?

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Artisan Partners Limited Partnership (4.15%), Janus Henderson Group PLC (3.48%), Brown Advisory Inc. (2.66%), Oak Ridge Investments LLC (2.33%), Fred Alger Management LLC (1.90%) and Kopp Family Office LLC (1.87%). Company insiders that own NeoGenomics stock include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics
.

Which major investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Kopp Family Office LLC, Dimensional Fund Advisors LP, Emerald Advisers LLC, Waddell & Reed Financial Inc., Uniplan Investment Counsel Inc., Royce & Associates LP, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, and Glenmede Trust Co. NA. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lawrence Martin Weiss, Oort Douglas M Van, Robert J Shovlin, Steven C Jones, and William Bonello.
View insider buying and selling activity for NeoGenomics
or view top insider-selling stocks.

Which major investors are buying NeoGenomics stock?

NEO stock was bought by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, Janus Henderson Group PLC, First Light Asset Management LLC, Compagnie Lombard Odier SCmA, Bellevue Group AG, Fred Alger Management LLC, Millennium Management LLC, and Geode Capital Management LLC.
View insider buying and selling activity for NeoGenomics
or or view top insider-buying stocks.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $43.57.

How much money does NeoGenomics make?

NeoGenomics has a market capitalization of $5.14 billion and generates $444.45 million in revenue each year. The medical research company earns $4.17 million in net income (profit) each year or $0.07 on an earnings per share basis.

How many employees does NeoGenomics have?

NeoGenomics employs 1,700 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

Where are NeoGenomics' headquarters?

NeoGenomics is headquartered at 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at (239) 768-0600 or via email at [email protected]


This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.